Dyne Therapeutics Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +14.4% | -30.5% | -5.9% | -31.8% | -99.8% | +0.0% | +48,766.7% | -42.6% | +62.2% | -63.0% | -100.0% | – | – | – | – | – | – | – | |
| – | -7.9% | -35.6% | -1.1% | -18.5% | -72.2% | +327.2% | +0.0% | +77.1% | +12.5% | +28.5% | -100.0% | +1,029.2% | +158.3% | +55.4% | +207.4% | -26.4% | -8.9% | -8.6% | |
| – | +55.6% | -24.9% | -10.4% | -45.5% | -142.6% | – | – | -469.5% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | +158.1% | +309.4% | +168.4% | +17.7% | +47.6% | +33.5% | +41.6% | |
| – | -22.7% | +1.3% | +2.5% | -17.2% | -83.7% | +340.9% | +0.0% | +32.0% | +25.8% | +17.4% | -99.7% | +438.9% | +382.7% | +113.6% | -1.8% | +11.3% | +99.0% | +11.8% | |
| – | – | – | – | -17.2% | -160.0% | – | -417.5% | – | +25.8% | +17.4% | -97.5% | +188.3% | +324.2% | +155.8% | +14.0% | +40.2% | +42.5% | +36.4% | |
| – | +17.2% | -217.6% | – | – | – | -144.5% | – | – | -1,100.0% | – | – | – | – | – | – | – | – | – | |
| – | +11.2% | -2.8% | -12.5% | -1.7% | -100.0% | – | -30.9% | +714.9% | +14.5% | -1.4% | -100.0% | +5,700.0% | +36.6% | +87.4% | +293.1% | -100.0% | – | – | |
| – | -7.9% | -650.8% | – | – | – | -579.3% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -37.5% | -420.8% | – | – | – | -505.1% | – | – | – | – | – | – | – | – | – | – | |
| – | -34.1% | -825.3% | – | – | – | -509.2% | – | – | -2,580.0% | – | -106.3% | – | – | – | – | – | – | – | |
| – | +8.7% | -119.2% | – | -314.4% | – | +32.7% | +94.7% | +152.1% | -85.6% | +795.3% | -100.5% | – | – | – | – | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.